BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the world’s leading
biopharmaceutical company, today announced that the results of a
number of hemophilia studies will be presented at the World
Federation of Hemophilia (WFH) 2010 Congress taking place July
10-14, 2010, in Buenos Aires, Argentina. Key research includes a
pre-clinical evaluation of recombinant factor Xa as a potential new
approach to restoring hemostasis, as well as a study assessing the
potential for an engineered recombinant factor VIIa molecule to
improve therapeutic outcomes in mouse models of hemophilia. These
presentations follow Pfizer’s recent announcement about the
creation of a new research unit focused on rare diseases, including
hemophilia.
“We are very excited to present these data, which highlights the
strength of our pipeline and our enduring commitment to provide
recombinant products for the hemophilia community,” says Brenda
Cooperstone, M.D., vice president of clinical development and
medical affairs for the Specialty Care Business Unit at Pfizer.
“Our investigation of novel therapies for hemophilia treatment
remains ongoing and we will continue to work closely with our
partners—including the World Federation of
Hemophilia—to help improve hemophilia care worldwide.”
Early Research with Factor Xa and VIIa
Pfizer will present the results of a pre-clinical study in mice
indicating that recombinant factor Xa therapy may provide a unique
way to bypass deficiencies in the intrinsic pathway. Additional
results from a preclinical study in mice suggest that a recombinant
factor VIIa molecule with increased activity and duration of action
may have the potential to improve inhibitor outcomes.
Additional Hemophilia Research from Pfizer at WFH
- New model of antibody-induced hemophilia A for the assessment
of bypass therapies - An electronic documentation system in Haemophilia provides
otherwise unavailable feedback for continuous quality control first
results from the Haemoassist® system - A prospective registry of European hemophilia B patients
receiving BeneFIX® (nonacog alfa, recombinant human factor IX)
for usual use - Two-year interim results of a non-interventional trial to
assess the safety and efficacy of treatment with recombinant factor
IX - Safety and efficacy of B-domain-deleted recombinant FVIII final
results of a 10 year pharmacovigilance study
Pfizer’s Ongoing Commitment to the WFH and the Hemophilia
Community
Pfizer will make a contribution to WFH at the meeting in support
of the Twinning Program, which aims to increase the level of
diagnosis and care for people with hemophilia by pairing emerging
treatment centers and patient organizations with more established
centers and organizations around the world. Wyeth, now part of
Pfizer, has acted as the exclusive corporate sponsor of the
world-renowned program since 2001, which currently has 32 Twinning
partnerships worldwide. Historically, there have been 149
Twinnings. Pfizer will also host the annual reception for the
Twinning Program.
